20

Nov

WHO advises against Gilead’s remdesivir for all hospitalised COVID-19 patients

Gilead's remdesivir is not recommended for patients hospitalised with COVID-19, regardless of how ill they are, as there is no evidence the drug improves survival or reduces the need for…

Read More Here

16

Oct

Gilead questions WHO study that cast doubts on drug’s COVID-19 benefits

Gilead Sciences Inc has questioned the findings of a World Health Organization (WHO) study that concluded its COVID-19 drug remdesivir does not help patients who have been admitted to hospital.…

Read More Here

14

Oct

Remdesivir cut COVID-19 recovery time by 5 days

Final data from a large study of Gilead Sciences Inc's antiviral drug remdesivir showed the treatment cut COVID-19 recovery time by five days among hospitalized patients, one day faster than…

Read More Here

08

Oct

EU signs joint procurement contract for remdesivir supply

The European Commission said on Thursday it had signed a contract with U.S. drugmaker Gilead for the supply of up to 500,000 treatment courses for remdesivir, sharply increasing the supply…

Read More Here

07

Oct

EU has agreed supply of 20,000 additional doses of Remdesivir

The European Commission said on Wednesday it had agreed with U.S. company Gilead the supply of more than 20,000 additional doses of its COVID-19 drug Remdesivir, in a bid to…

Read More Here

06

Oct

European countries facing shortage of Covid-19 drug remdesivir

European countries are facing shortages of COVID-19 drug remdesivir because limited supplies are running out, officials said, with cases surging and the United States having bought up most of drugmaker…

Read More Here

02

Jul

World takes stock of COVID-19 drug remdesivir after U.S. snaps up supplies

Some governments in Europe and Asia said they have enough of Gilead’s COVID-19 anti-viral remdesivir for now despite fears of shortages since the U.S. drugmaker pledged most output to its…

Read More Here

02

May

EU drugs agency evaluates potential coronavirus treatment

The European Medicines Agency said Thursday it will start a rolling review of remdesivir, an investigational therapy for COVID-19 originally developed by drugmaker Gilead to treat Ebola. EMA’s human medicines committee…

Read More Here

24

Apr

Gilead disputes report that its drug flopped in leaked coronavirus trial

A closely-watched Gilead Sciences Inc experimental antiviral drug failed to help patients with severe COVID-19 in a clinical trial conducted in China, but the drugmaker said the findings were inconclusive…

Read More Here

24

Apr

Potential antiviral drug for coronavirus fails in its first clinical trial

A potential antiviral drug for the coronavirus has reportedly failed in its first randomised clinical trial. There had been widespread hope that remdesivir could treat Covid-19. But a Chinese trial…

Read More Here